Weight-Loss Drugs Set for Prescription Without Doctor's Visit

Pharmacists are preparing to distribute weight-loss injections soon. NHS .

As per government proposals, obtaining medications such as Ozempic and Mounjaro would require only a brief counter-side discussion, costing merely an NHS prescription fee—which currently stands at £9.90.

The Mail reports that a significant agreement valued at tens of millions of pounds is set to be made with a leading pharmaceutical company to finance a trial program throughout the UK, with plans to ultimately extend it to all who require assistance.

Currently, these potent treatments are accessible to just a small group of individuals through the NHS—following consultations with specialists and alongside other weight-reduction strategies. The wait for this treatment extends over approximately two years.

However, ministers intend to significantly broaden the usage of these medications by readily and effortlessly providing prescriptions through innovative methods like local pharmacy chains, healthcare centers, and applications.

This implies that once the agreement is finalized, you'll be able to enter a pharmacy, undergo a brief evaluation, and then depart with a dose of vaccines for £9.90.

According to a source: "Individuals with means are already securing these opportunities privately, however, we are aware that individuals from specific backgrounds consistently get overlooked when it comes to such forms of assistance."

This ensures that local pharmacies and reliable healthcare organizations are engaged in the implementation process right from the start.

Over a quarter (28 percent) of adults in England are considered obese, with an additional 36 percent being overweight. This obesity epidemic places a burden of over £6 billion annually on the NHS and causes further significant economic losses due to reduced productivity and increased benefit payments.

Weight loss injections can be purchased directly from retail pharmacists or online drugstores after a brief consultation with a pharmacist. These typically range in price from £120 to £250 per month’s supply.

It is estimated that around 500,000 individuals in Britain have received these injections, often through private means. Clinical trial participants reportedly shed between 15 to 20 percent of their body weight, varying according to the specific medication used.

Given that the nation has around 14 million individuals who are obese, implementing such measures for everybody simultaneously might drain the NHS resources, hence it should be introduced progressively.

On the other hand, critics argued that taxpayers shouldn’t have to cover the costs of ‘fashionable’ medications, which wouldn’t be necessary if individuals opted for more healthful living.

Katharine Jenner, director of the Obesity Health Alliance, stated that patients should be supervised by experts capable of ensuring the safe use of these medications.

"Obesity is a long-term, recurring ailment with numerous contributing factors," she stated.

We embrace investments that provide assistance to individuals dealing with overweight issues and require necessary support—but medications alone do not suffice.

John O'Connell, who leads the TaxPayers' Alliance, remarked: "Taxpayers have every right to wonder if distributing weight-loss medications so extensively represents the most effective utilization of their funds."

Although addressing obesity is crucial, ministers should guarantee that this program provides good value for money and does not lead to uncontrolled expenses or inefficiency.

Professor Kamila Hawthorne, chairperson of the Royal College of General Practitioners, stated: "There is significant potential in weight-loss medications."

To assist patients having difficulty losing weight, and who fulfill all the necessary clinical requirements for receiving a prescription.

However, these medications shouldn’t be viewed as an instant solution for shedding pounds or a quick way to reach a specific weight target.

The upcoming implementation must undergo regular assessments to confirm that these guidelines provide lasting advantages for patients. Additionally, we need to verify that primary care services along with the broader NHS have adequate capabilities and resources to deliver treatments securely.

This development occurred as the World Health Organization was set to formally approve weight-loss medications aimed at addressing adult obesity for the first time. A leaked memorandum obtained by Reuters disclosed this reversal, following earlier statements from the WHO indicating they couldn’t advocate these drugs due to insufficient information regarding their long-term impacts.

This suggestion might result in adding these medications not only to their recommended list but also to their essential medicines roster, potentially increasing global accessibility.

Read more